DGCR8 Antikörper (N-Term)
Kurzübersicht für DGCR8 Antikörper (N-Term) (ABIN633303)
Target
Alle DGCR8 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Spezifität
- DGCR8 antibody was raised against the N terminal of DGCR8
-
Aufreinigung
- Affinity purified
-
Immunogen
- DGCR8 antibody was raised using the N terminal of DGCR8 corresponding to a region with amino acids DKKDEENELDQEKRVEYAVLDELEDFTDNLELDEEGAGGFTAKAIVQRDR
-
-
-
-
Applikationshinweise
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
DGCR8 Blocking Peptide, (ABIN937407), is also available for use as a blocking control in assays to test for specificity of this DGCR8 antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of DGCR8 antibody in PBS
-
Konzentration
- Lot specific
-
Buffer
- PBS
-
Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- DGCR8 (DiGeorge Syndrome Critical Region Gene 8 (DGCR8))
-
Andere Bezeichnung
- DGCR8
-
Hintergrund
- DGCR8 contains 2 DRBM (double-stranded RNA-binding) domains and 1 WW domain. It may play a part in the etiology of the velocardiofacial/DiGeorge syndrome (VCFS/DGS), a developmental disorder characterized by structural and functional palate anomalies, conotruncal cardiac malformations, immunodeficiency, hypocalcemia, and typical facial anomalies.
-
Molekulargewicht
- 85 kDa (MW of target protein)
-
Pathways
- Regulatorische RNA Pathways
Target
-